

Jean Michel Pawlotsky

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7537772/jean-michel-pawlotsky-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

68

papers

5,041

citations

30

h-index

71

g-index

76

ext. papers

6,433

ext. citations

10.5

avg, IF

6.72

L-index

#	Paper	IF	Citations
68	Case Report: Cerebral Nocardiosis Caused by Detected by Metagenomics in an Apparently Immunocompetent Patient.. <i>Frontiers in Immunology</i> , 2022 , 13, 719124	8.4	1
67	Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology.. <i>Journal of Hepatology</i> , 2022 ,	13.4	6
66	Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2.. <i>EBioMedicine</i> , 2022 , 77, 103934	8.8	2
65	Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant.. <i>Immunity</i> , 2022 ,	32.3	2
64	Prospective Comparison Between Shotgun Metagenomics and Sanger Sequencing of the 16S rRNA Gene for the Etiological Diagnosis of Infections.. <i>Frontiers in Microbiology</i> , 2022 , 13, 761873	5.7	0
63	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.. <i>JHEP Reports</i> , 2022 , 4, 100462	10.3	1
62	Alinity m, a Random-Access System, for Hepatitis B Virus DNA Quantification in Plasma and Whole Blood Collected on Dried Blood Spots.. <i>MSphere</i> , 2022 , e0008222	5	
61	Performance of a high-throughput, automated enzyme immunoassay for the detection of SARS-CoV-2 antigen, including in viral "variants of concern": Implications for clinical use. <i>Journal of Clinical Virology</i> , 2021 , 146, 105048	14.5	1
60	Diagnosis and Monitoring of Hepatitis B Virus Infection Using the Cobas HBV Test for Use on the Cobas 4800 System. <i>Microorganisms</i> , 2021 , 9,	4.9	1
59	Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. <i>Cell</i> , 2021 , 184, 1201-1213.e14	36.2	110
58	Viral genomic, metagenomic and human transcriptomic characterization and prediction of the clinical forms of COVID-19. <i>PLoS Pathogens</i> , 2021 , 17, e1009416	7.6	7
57	BNT162b2 mRNA vaccination did not prevent an outbreak of SARS COV-2 variant 501Y.V2 in an elderly nursing home but reduced transmission and disease severity. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	19
56	Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	4
55	Tissue damage induces a conserved stress response that initiates quiescent muscle stem cell activation. <i>Cell Stem Cell</i> , 2021 , 28, 1125-1135.e7	18	22
54	Fatal encephalitis caused by Newcastle disease virus in a child. <i>Acta Neuropathologica</i> , 2021 , 142, 605-608	14.3	1
53	Impact of COVID-19 on global HCV elimination efforts. <i>Journal of Hepatology</i> , 2021 , 74, 31-36	13.4	80
52	A Phenyl-Pyrrolidine Derivative Reveals a Dual Inhibition Mechanism of Myocardial Mitochondrial Permeability Transition Pore, Which Is Limited by Its Myocardial Distribution. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021 , 376, 348-357	4.7	2

51	Variable In Vivo Hepatitis D Virus (HDV) RNA Editing Rates According to the HDV Genotype. <i>Viruses</i> , 2021 , 13,	6.2	3
50	Differential anti-S antibody titers in vaccinated residents during an outbreak of SARS-CoV-2 variant B.1.351 (Δ) in an elderly nursing home. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	1
49	mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. <i>Immunity</i> , 2021 ,	32.3	29
48	Microdiversity of isolates in cases of infective endocarditis: selection of non-synonymous mutations and large deletions is associated with phenotypic modifications. <i>Emerging Microbes and Infections</i> , 2021 , 10, 929-938	18.9	3
47	Progress towards hepatitis C virus elimination in high-income countries: An updated analysis. <i>Liver International</i> , 2021 , 41, 456-463	7.9	25
46	Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025). <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	35
45	Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. <i>BMJ, The</i> , 2020 , 369, m1844	5.9	266
44	COVID-19 and the liver-related deaths to come. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 523-525	24.2	30
43	SARS-CoV-2 viral loads and serum IgA/IgG immune responses in critically ill COVID-19 patients. <i>Intensive Care Medicine</i> , 2020 , 46, 1781-1783	14.5	22
42	Evaluation of the Xpert HBV Viral Load for hepatitis B virus molecular testing. <i>Journal of Clinical Virology</i> , 2020 , 129, 104481	14.5	7
41	Predicting Survival After Hepatocellular Carcinoma Resection Using Deep Learning on Histological Slides. <i>Hepatology</i> , 2020 , 72, 2000-2013	11.2	59
40	COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2191-2194	11.6	14
39	Fitness-associated substitutions following failure of direct-acting antivirals assessed by deep sequencing of full-length hepatitis C virus genomes. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1583-1591	6.1	2
38	EASL recommendations on treatment of hepatitis C: Final update of the series. <i>Journal of Hepatology</i> , 2020 , 73, 1170-1218	13.4	237
37	Small-Molecule Inhibitors of Cyclophilins Block Opening of the Mitochondrial Permeability Transition Pore and Protect Mice From Hepatic Ischemia/Reperfusion Injury. <i>Gastroenterology</i> , 2019 , 157, 1368-1382	13.3	33
36	Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures. <i>Seminars in Liver Disease</i> , 2019 , 39, 354-368	7.3	21
35	Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. <i>Hepatology</i> , 2019 , 70, 771-787	11.2	28
34	Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r. <i>Hepatology</i> , 2019 , 69, 513-523	11.2	57

33	Indeterminate genotypes of hepatitis C virus by the Abbott RealTime HCV Genotype II assay in Morocco. About eight cases resolved by a sequencing method. <i>Journal of Medical Virology</i> , 2018 , 90, 1352-1357	19.7	1
32	EASL Recommendations on Treatment of Hepatitis C 2018. <i>Journal of Hepatology</i> , 2018 , 69, 461-511	13.4	1079
31	Chronic hepatitis B virus infection. <i>Lancet, The</i> , 2018 , 392, 2313-2324	40	206
30	Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	7
29	The New Aptima HBV Quant Real-Time TMA Assay Accurately Quantifies Hepatitis B Virus DNA from Genotypes A to F. <i>Journal of Clinical Microbiology</i> , 2017 , 55, 1211-1219	9.7	13
28	Evaluation of a new random-access HBV DNA molecular assay: The VERIS HBV assay. <i>Journal of Clinical Virology</i> , 2017 , 92, 69-74	14.5	6
27	Hepatitis C virus induces a prediabetic state by directly impairing hepatic glucose metabolism in mice. <i>Journal of Biological Chemistry</i> , 2017 , 292, 12860-12873	5.4	15
26	The New Aptima HCV Quant Dx Real-time TMA Assay Accurately Quantifies Hepatitis C Virus Genotype 1-6 RNA. <i>Journal of Clinical Virology</i> , 2017 , 91, 5-11	14.5	16
25	Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains. <i>Hepatology</i> , 2017 , 66, 1826-1841	11.2	55
24	Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. <i>Hepatology</i> , 2016 , 64, 2038-2046	11.2	242
23	Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities. <i>Nature Communications</i> , 2016 , 7, 12777	17.4	44
22	Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. <i>Hepatology</i> , 2016 , 63, 1809-16	11.2	51
21	Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. <i>Gastroenterology</i> , 2016 , 151, 70-86	13.3	402
20	HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals. <i>Antiviral Therapy</i> , 2015 , 20, 177-83	1.6	16
19	Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. <i>Hepatology</i> , 2015 , 62, 1013-23	11.2	39
18	Virologic Tools for HCV Drug Resistance Testing. <i>Viruses</i> , 2015 , 7, 6346-59	6.2	37
17	HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc. <i>PLoS ONE</i> , 2015 , 10, e0127816	3.7	3
16	Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014. <i>Gastroenterology</i> , 2015 , 148, 468-79	13.3	41

15	Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. <i>Gastroenterology</i> , 2014 , 147, 132-142.e4	13.3	207
14	Direct-acting antiviral agents and the path to interferon independence. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 728-37	6.9	32
13	New hepatitis C therapies: the toolbox, strategies, and challenges. <i>Gastroenterology</i> , 2014 , 146, 1176-92	13.3	408
12	NS5A inhibitors in the treatment of hepatitis C. <i>Journal of Hepatology</i> , 2013 , 59, 375-82	13.4	155
11	New virologic tools for management of chronic hepatitis B and C. <i>Gastroenterology</i> , 2012 , 142, 1303-1313.e1	13.3	97
10	Drug resistance: Prevalence and clinical implications during the treatment of chronic hepatitis C infection. <i>Clinical Liver Disease</i> , 2012 , 1, 58-61	2.2	2
9	Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG. <i>Gastroenterology</i> , 2011 , 140, 755-60	13.3	31
8	Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. <i>Hepatology</i> , 2011 , 53, 1742-51	11.2	257
7	Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. <i>Journal of Clinical Microbiology</i> , 2010 , 48, 3641-7	9.7	50
6	Characterization of V36C, a novel amino acid substitution conferring hepatitis C virus (HCV) resistance to telaprevir, a potent peptidomimetic inhibitor of HCV protease. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 2681-3	5.9	15
5	Dynamics of hepatitis B virus resistance to lamivudine. <i>Journal of Virology</i> , 2006 , 80, 643-53	6.6	80
4	Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. <i>Journal of Virology</i> , 1999 , 73, 6490-9	6.6	71
3	Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations. <i>Journal of Virology</i> , 1998 , 72, 2795-805	6.6	162
2	Immune escape of SARS-CoV-2 Omicron variant from mRNA vaccination-elicited RBD-specific memory B cells		2
1	Memory B cells control SARS-CoV-2 variants upon mRNA vaccination of naive and COVID-19 recovered individuals		5